Results 21 to 30 of about 15,373 (177)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial [PDF]

, 2019
IMPORTANCE Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating ...
Mousa, K, Saura, C, Conibear, J, Moosa, A, Coetzee, C, Schmid, P, Lawrence, C, Makris, A, Ferreira, M, Nemsadze, G, Cortés, J, Kristeleit, H, Kuemmel, S, Schenker, M, Lee, KS, Kendall, A, Sarker, S-J, Brunt, AM, Ruiz, I, Harper-Wynne, C, Prendergast, A, Zaiss, M, Chan, S, Sohn, J, Dubey, S, Oelmann, E, Shepherd, CJ, Perelló, A, Grenier, J, Máhr, K, Brown, J, Marosics, P   +31 more
core   +3 more sources

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

npj Breast Cancer, 2021
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed.
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty   +26 more
doaj   +1 more source

Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. [PDF]

PLoS ONE, 2014
Fulvestrant (ICI-182,780) has recently been shown to effectively suppress prostate cancer cell growth in vitro and in vivo. But it is unclear whether microRNAs play a role in regulating oncogene expression in fulvestrant-treated prostate cancer.
Yuet-Kin Leung, Queeny Kwan-Yi Chan, Chi-Fai Ng, Fanny Man-Ting Ma, Ho-Man Tse, Ka-Fai To, Jodi Maranchie, Shuk-Mei Ho, Kin-Mang Lau   +8 more
doaj   +1 more source

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

, 2022
PURPOSE: This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant.
Jerez, Yolanda, Lahuerta, Ainhara, Alonso-Romero, José Luis, García-Sáenz, José Á., Slamon, Dennis, Leonard, E Jane, Alonso-Romero, Jose L., Alonso-Romero, Jose L, Carrasco, Eva, González-Santiago, Santiago, Ramos, Manuel, Vincent, Sylvie, Ferrer, Nieves, Galinsky, Kevin, Chen, Jingjing, García-Sáenz, José Á, Neuwirth, Rachel, Martínez-Jáñez, Noelia, Cubedo, Ricardo, Antón, Antonio, Leonard, E. Jane   +20 more
core   +1 more source

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. [PDF]

PLoS ONE, 2013
Fulvestrant is a representative pure antiestrogen and a Selective Estrogen Receptor Down-regulator (SERD). In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor α (ERα) as antagonists ...
Wei-Lan Yeh, Keiko Shioda, Kathryn R Coser, Danielle Rivizzigno, Kristen R McSweeney, Toshi Shioda   +5 more
doaj   +1 more source

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

Breast Cancer Research, 2021
Background In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR 0.757) compared with placebo plus ...
Patrick Neven, Hope S. Rugo, Sara M. Tolaney, Hiroji Iwata, Masakazu Toi, Matthew P. Goetz, Peter A. Kaufman, Yi Lu, Nadine Haddad, Karla C. Hurt, George W. Sledge   +10 more
doaj   +1 more source

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer, 2021
Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to ...
Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor, Ayako Suzuki, James H. Lewis, James W. Freston, Stephan Lanes   +8 more
doaj   +1 more source

Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy

Breast Cancer Research, 2023
Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infiltrating ...
Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler   +10 more
doaj   +1 more source

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. [PDF]

, 2021
Lessons learnedFulvestrant is a selective estrogen receptor (ER)-downregulating antiestrogen that blocks ER transcriptional activity and is approved for ER-positive breast cancer.
Lewis, Lionel, Romo, Bianca, Marotti, Jonathan, Shee, Kevin, Kisselev, Alexei, Miller, Todd, Schwartz, Gary   +6 more
core   +1 more source

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome

Cancer Research, Statistics, and Treatment, 2020
Background: Fulvestrant has been shown to improve survival in hormone-positive, HER2-negative advanced breast cancer (ABC). There is no study on fulvestrant from India.
Indhuja Muthiah Vaikundaraja, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiarasi, Nikita Mehra, Arun Kumar Rajan, Gangothri Selvarajan, Siva Sree Kesana, Balasubramanian Ananthi, Priya Iyer, Geetha Senguttuvan, Manjula Rao, Arvind Krishnamurthy, Sridevi Velusamy, Hemanth Raj, Rama Ranganathan, Shirley Sundersingh, Selvaluxmy Ganesarajah, Trivadi S Ganesan, Tenali Gnana Sagar   +19 more
doaj   +1 more source